Loading
Breast Cancer Treatment Studies / Endometrial and Cervical Cancer Treatments · Journal article
Acta Oncologica · August 11, 2026
Reinforces what was already believed, rather than introducing something new.
In a population-based cohort of 1219 women with endometrial cancer, isolated tumor cells and nodal tumor burden (bulk, macro-, or micro-metastases) were not independently associated with overall or cancer-specific survival after adjustment for age, p53 mutation status, and other clinical factors. The confidence intervals are wide and consistent with clinically meaningful associations, so modest prognostic effects cannot be excluded.
Population-based cohort study. Women with endometrial cancer undergoing surgery in Region Stockholm-Gotland, Sweden, 2010–2024; either sentinel lymph node biopsy or FIGO stage IIIC nodal metastases.. Intervention: Nodal assessment by sentinel lymph node biopsy or registration of nodal metastases; categorization by nodal burden (bulky, macro-, micro-metastases, or isolated tumor cells).. Compared with: For isolated tumor cells: node-negative patients. For nodal burden: micrometastases (reference) versus macrometastases and bulky metastases.. n = 1,219. Region Stockholm-Gotland, Sweden.
Among 1219 patients, 310 (25%) had nodal dissemination, including 250 with nodal metastases and 60 with isolated tumor cells Isolated tumor cells versus node-negative: HR 1.94 (95% CI 0.75–5.06), not statistically significant Among node-positive patients, macrometastases versus micrometastases: HR 0.95 (95% CI 0.50–1.81); bulky versus micrometastases: HR 1.19 (95% CI 0.64–2.21), neither significant
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
These findings suggest that isolated tumor cells and nodal tumor burden may not independently warrant changes in adjuvant treatment decisions in endometrial cancer beyond established risk factors. However, the wide confidence intervals mean modest prognostic effects remain possible, and clinicians should continue to integrate nodal findings with patient age and molecular markers (p53 status) in treatment planning.
Population-based cohort study with adequate sample size showing that isolated tumor cells and nodal burden lack prognostic significance in endometrial cancer after adjustment for clinical and molecular factors, confirming that current nodal assessment practices may not require stratification by these markers.
As stated by the source record.
Quoted from the source exactly as published.
These findings suggest that isolated tumor cells and nodal tumor burden may not independently warrant changes in adjuvant treatment decisions in endometrial cancer beyond established risk factors. However, the wide confidence intervals mean modest prognostic effects remain possible, and clinicians should continue to integrate nodal findings with patient age and molecular markers (p53 status) in treatment planning.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
BACKGROUND AND PURPOSE: Since the introduction of sentinel lymph node biopsy, nodal assessment has expanded to nearly all women with endometrial cancer. However, evidence on the prognostic significance of isolated tumor cells (ITCs) and nodal tumor burden remains limited. We therefore investigated the association of ITCs and nodal tumor burden with survival. PATIENTS AND METHODS: This cohort study included women with endometrial cancer who underwent surgery in Region Stockholm-Gotland, Sweden, between 2010 and 2024, and either underwent sentinel lymph node biopsy or were registered as having lymph node metastases (FIGO stage IIIC). Nodal dissemination was categorized as bulky, macro-, micro-metastases, or ITCs. Overall survival (OS) and cancer-specific survival (CSS) were evaluated using multivariable Cox regression in two separate analyses: (1) ITCs versus node-negative patients and (2) nodal tumor burden (bulky, macro-, micro-metastases) among node-positive patients. RESULTS: Among 1219 patients, 310 (25%) had nodal dissemination, including 250 with nodal metastases and 60 with ITCs. No significant difference in OS was observed between patients with ITCs and node-negative patients (Hazard ratio [HR] 1.94, 95% confidence interval [CI] 0.75-5.06). Adjuvant therapy was more frequent among patients with ITCs (47% vs. 11%). In patients with nodal metastases, no clear OS differences were observed by nodal burden. Compared with micrometastases, survival was similar for macrometastases (HR 0.95, 95% CI 0.50-1.81) and bulky metastases (HR 1.19, 95% CI 0.64-2.21). Age > 68 years and p53 mutation were associated with worse survival. CSS analyses yielded similar findings, with no significant differences observed in either comparison. INTERPRETATION: Neither ITCs nor greater nodal burden was clearly associated with survival after adjustment for clinical and molecular factors. Survival appeared to be influenced by patient and tumor characteristics, although estimates were imprecise and modest associations cannot be excluded.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.